Business · 11/01/2023
FDA Announces Model-Informed Drug Development Approaches Program Under PDUFA VII
The FDA is continuing the Model-Informed Drug Development (MIDD) Paired Meeting Program to advance model-informed drug development approaches in medical product development, as part of the Prescription Drug User Fee Act of 2023 (PDUFA VII) and the FDA User Fee Reauthorization Act of 2022.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →